US Stock MarketDetailed Quotes

AKRO Akero Therapeutics

Watchlist

50.520
+1.290+2.62%

Close Feb 14 16:00 ET

50.520
0.0000.00%

Post 20:01 ET

3.85BMarket Cap-13.37P/E (TTM)

Akero Therapeutics Stock Forum

Jaguar8

Jan 27 06:38

NEWS

$Akero Therapeutics (AKRO.US)$
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
Akero Therapeutics (NASDAQ: AKRO) has announced significant topline results from its Phase 2b SYMMETRY study evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to MASH. The study demonstrated statistically significant reversal of c...

Jaguar8

Jan 27 06:37

😍😍😍

$Akero Therapeutics (AKRO.US)$

Jaguar8

Jan 26 15:36

🟠 Watchlist, JANUARY 27,2025, Monday. NFA - DrJag8 (Those who will put other stocks and their picks in comment will be blocked. Make your own list and post instead)

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after ...

Jaguar8

Jan 24 15:27

Take note Monday, January 27, 8AM ET result of SYMMETRY study on MASH cirrhosis

$Akero Therapeutics (AKRO.US)$

Jaguar8

Jan 24 15:26

NEWS

$Akero Therapeutics (AKRO.US)$
Akero To Announce SYMMETRY Study Phase 2b Results For Efruxifermin In MASH Cirrhosis; Investor Webcast Set For Jan. 27 At 8 AM ET
Benzinga
·
About the SYMMETRY Study
The Phase 2b SYMMETRY study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in adult patients with biopsy-confirmed compensated cirrhosis (F4, Child-Pugh A) due to MASH. The study enrolled a total of 182 patients, randomized to receive once-weekly subcutaneous dos...